A phase II, multicentre, double-blind, randomised, dose range finding placebo controlled study of rifaximin-EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn's disease

Trial Profile

A phase II, multicentre, double-blind, randomised, dose range finding placebo controlled study of rifaximin-EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2013

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Retic-03
  • Most Recent Events

    • 28 Jun 2012 Planned number of patients changed from 410 to 424 as reported by European Clinical Trials Database.
    • 06 Dec 2011 Results published in the Gastroenterology.
    • 06 Dec 2011 Primary endpoint 'Remission-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top